A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

Summary

The primary objective of this study is to compare the change in estimated glomerular filtration rate (eGFR) from baseline to Week 8 between placebo and GCS-100 treatment. The secondary objective is to determine the safety and tolerability of GCS-100 administered for 8 weeks relative to placebo. In addition, the study will measure the effect of GCS-100 on circulating galectin-3 and other markers of disease activity.

Timeline

Start

2013-06

Primary completion

2014-02

Completion

2014-09

Drugs

Indications